Innovation-driven responses to the COVID-19 crisis

Click to open PDF

　　　 COVID-19 Life Science Webinar annoncement FINAL En.pdf

The world face an unprecedented crisis in the COVID-19 pandemic and Denmark has not been spared. On February 27 the virus was confirmed to have spread to Denmark, followed by a countrywide lockdown from March 13 to April 15.
It is a race against time to keep the outbreak under control and ensure sufficient healthcare capacity to handle the excess number of COVID-19 patients. For some countries, where the healthcare system is already under extreme pressure, a race to increase capacity immediately, and for other countries, a race to plan ahead and ensure capacity, according to forecasts.
In this critical situation, public healthcare authorities, companies large and small and universities stand united to combine all resources to step up capacity to handle the crisis.
Sometimes a crisis can serve as a catalyst to innovation and in this webinar we will highlight and showcase some examples of medical innovation coming out of the pandemic.
Healthcare Denmark, a public-private partnership organization, will provide an overview of how the triple helix turned to innovation to create new solutions and leverage existing technologies to combat the pandemic.
In addition, we will hear from three companies who have leveraged their existing technologies to fight COVID-19.

Date and Time:

September 29, 2020,Tuesday. 16:00 – 17:30

Venue:

ZOOM Webinar

Registration

(Opens an external site)

Participation fee

Free

Speaker Introductions

Healthcare DENMARK
Hans Erik Henriksen is CEO of Healthcare DENMARK. Healthcare DENMARK is a public-private partnership organization, with a national mandate to promote Danish healthcare solutions and competencies abroad. The partnership is a framework for linking international partners with efficient Danish solutions and does not represent individual companies.
Hans Erik has a solid healthcare background from different executive positions during the latest 20 years.

ExpreS2ion Biotechnologies
ExpreS2ion Biotechnologies is a biotech company that combines a unique production platform, ExpreS2, for fast and efficient development of new therapeutics and diagnostics, and a universal capsid virus-like particle (cVLP) technology through its joint venture AdaptVac, to offer competitive recombinant protein services, as well as build a high value pipeline of vaccines within infectious diseases and cancer. AdaptVac and ExpreS2ion develop a unique COVID-19 vaccine together with Danish company Bavarian Nordic and Japanese AGC Biologics.
ExpreS2ion is publicly listed on NASDAQ First North Growth Market Stockholm through ExpreS2ion Biotech Holding AB (Ticker: EXPRS2).
Mr. Bent U. Frandsen, Chief Executive Officer, is employed in ExpreS2ion since 2016 and was appointed CEO in 2019. He entered the board of AdaptVac ApS in 2017. He has more than 25 years of professional experience in management, finance, and business development positions in multinational companies, including more than 20 years life science experience at public listed companies: Lundbeck, ALK-Abelló, Coloplast, and private companies: NsGene, CMC Biologics, and Amphidex.
Mr. Frandsen holds a MSc in Finance and Strategic Planning from Copenhagen Business School, Denmark.

Immunitrack
The current COVID-19 pandemic, caused by the SARS-CoV-2 virus, has placed an urgent demand on vaccine development, and a number of public and private initiatives are focused on this task. Immunitrack is committed to playing its role in the fight against COVID-19 by applying its technology to support vaccine development and immune monitoring in infected and recovered COVID-19 patients. Immunitrack is founded upon world-leading academic research on MHC-epitope binding. Using our deep knowledge in this area, we have developed the proprietary epitope screening platform technology, NeoScreen®. NeoScreen® accurately assays the affinity and stability of MHC/epitope interactions, and the technology has the capacity to rapidly screen libraries with thousands of (neo-)epitopes for applications within immune-oncology, vaccine production, T cell therapies and immune monitoring.
Dr. Stephan Thorgrimsen, CEO of Immunitrack, is one of Immunitrack’s two co-founders. He holds a PhD in biochemistry from the University of Copenhagen, Denmark and he authored or co-authored numerous peer-reviewed articles during his research career.

2N and Telehealth Japan
2N Group is a Nordic telehealth provider with years of experience from the field of remote monitoring, diagnostics and support for the patients.
As the latest addition to our telehealth services 2N Group and Kameda IT have established a joint venture for Japanese market in 2020. TeleHealth Japan K.K. shall combine universal telehealth tools and adjust them for local needs in Japan.
Together with healthcare professionals we are reinventing the ways to treat patients. Telehealth will bring healthcare available for all of us.
Mrs. Ekman has over 20 years of legal and commercial experience around export and international business. Having practiced law as an attorney-at-law and acted as legal council for several international organizations, she moved into senior commercial and business development roles. Prior to establishing 2N Group in 2020 Hanna worked as Executive Vice President and Director of Business Development at Emtele Ltd, information technology company. In Emtele Ltd she was responsible for global telehealth business development.

Invest in Denmark
Invest in Denmark is part of the The Ministry of Foreign Affairs of Denmark. The mission of Invest in Denmark is to service foreign companies considering the possibility of establishing business operations in Denmark. Through active, focused marketing efforts in North America, Asia and Europe, potential investors are given an insight into the business opportunities that Denmark can offer. The goal is to maintain and attract foreign direct investment to Denmark, thereby strengthening the globalization of Danish business and increasing the level of competence and knowledge.
Dr. Rasmus Beedholm-Ebsen is Senior Advisor within Life Science, at Invest in Denmark, under the Ministry of Foreign Affairs of Denmark. Dr Beedholm-Ebsen received his PhD in Medicine at Aarhus University, Denmark, and worked at the University of Utah in the Department of Biochemistry, before joining Invest in Denmark. Dr Beedholm-Ebsen also hold a Master degree in Molecular Biology, and is Scientific Expert Reviewer for the European Commission.